Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ: COAG · Real-Time Price · USD

25.89

-0.41 (-1.56%)

At close: May 22, 2026, 4:00 PM EDT

27.02

+1.13 (4.36%)

After-hours: May 22, 2026, 6:37 PM EDT

COAG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-63.91	-48.71
Depreciation & Amortization	0.3	0.25
Stock-Based Compensation	2.01	1.91
Other Adjustments	-1.23	-0.49
Changes in Accounts Payable	2.58	0.91
Changes in Accrued Expenses	1.51	1.36
Changes in Other Operating Activities	-2.73	-0.82
Operating Cash Flow	-61.48	-45.59
Capital Expenditures	-0.02	-0.28
Purchases of Investments	-252.5	-53.29
Proceeds from Sale of Investments	171.03	115.47
Investing Cash Flow	-81.48	61.9
Long-Term Debt Repaid	-0.12	-0.1
Net Long-Term Debt Issued (Repaid)	-0.12	-0.1
Issuance of Preferred Stock	156.42	-
Net Preferred Stock Issued (Repurchased)	156.42	-
Financing Cash Flow	156.3	-0.1
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.22	-
Net Cash Flow	13.57	16.21

Updated May 21, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q